

2019 Operating Grants Competition Results

The Cancer Research Society's Board of Directors approved a budget of **\$8.9 million** for **74** new projects


- 36 funded by the Cancer Research Society
- 38 funded in partnership with different organizations or families

→ **Overall Success Rate*: 20.7%**

- ✦ Men: 20.5%
- ✦ Women: 21.2%
- ✦ Young Investigators: 21.7%
- ✦ Renewals: 40%


The financial support granted by the **Cancer Research Society** is made possible thanks to the generosity of our donors and partners. *We know that we can count on your support in our future fundraising campaigns!*

Grants Awarded by Province







*not considering withdrawn applications


2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Addison, Christina Ottawa Hospital Research Institute	Uncovering mechanisms of resistance to CDK inhibition in breast cancer	\$ 120,000/ 2 years <i>Funded in partnership with the Ottawa Hospital Research Institute</i> 
Ailles, Laurie University Health Network	Identification of prognostic biomarkers and novel targets for head and neck cancer patients	\$ 120,000/ 2 years
Alain, Tommy Children's Hospital of Eastern Ontario Research Institute	Establishing novel pharmaco-viral approaches for the treatment of brain cancer.	\$ 120,000/ 2 years
Al-awar, Rima Ontario Institute for Cancer Research	Evaluation of CDC40 as a therapeutic target for lung cancer	\$ 120,000/ 2 years


2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Antonescu, Costin Ryerson University	Metabolic and mitogenic cues regulate glycogen synthase kinase 3 β localization dynamics to impact cancer cell survival and growth	\$ 120,000/ 2 years <i>Funded in partnership with the Canadian Institutes of Health Research</i> 
Ardolino, Michele Ottawa Hospital Research Institute	A little help from a... foe: PD-L1 facilitates oncolytic virus therapy in prostate cancer.	\$ 120,000/ 2 years <i>Funded in partnership with the University of Ottawa</i> 
Asfaha, Samuel Western University	Defining the cellular origin of colorectal cancer.	\$ 120,000/ 2 years <i>Funded in partnership with the Canadian Institutes of Health Research</i> 
Bailey, Swneke Research Institute of the McGill University Health Centre	Identifying somatically acquired molecular events promoting the progression of esophago-gastric adenocarcinoma to peritoneal metastasis	\$ 120,000/ 2 years <i>Funded in partnership with the Canadian Institutes of Health Research</i> 

2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Bapat, Bharati</i> Lunenfeld-Tanenbaum Research Institute	Exploring circular RNAs in liquid biopsies for improved prognostication of renal cell carcinoma among patients presenting with small renal masses	\$ 120,000/ 2 years <i>Funded through our Give for a Cure campaign, with the support of researchers, employees and CRS Board Members</i>
<i>Beauchemin, Nicole</i> McGill University	Susceptibility to immune-mediated colitis-associated colorectal cancer	\$ 120,000/ 2 years
<i>Bennewith, Kevin</i> BC Cancer	The influence of eosinophils and B cells on metastatic tumour growth in the lungs	\$ 120,000/ 2 years
<i>Benoit, Yannick</i> University of Ottawa	Selective inhibition of H3K9 dimethylation in colon cancer stem cells using a repurposed drug initially developed to treat cocaine addictions	\$ 120,000/ 2 years <i>Funded in partnership with the University of Ottawa</i>  uOttawa





2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Beug, Shawn</i> Children's Hospital of Eastern Ontario Research Institute	Understanding the tumour immunological landscape in response to IAP antagonists to direct future trials	\$ 120,000/ 2 years
<i>Bhavsar, Amit</i> University of Alberta	Investigating the role of cisplatin metabolism in the development of ototoxicity during childhood cancer treatment	\$ 120,000/ 2 years
<i>Burchell, Ann</i> St. Michael's Hospital	Effectiveness of human papillomavirus vaccine among gay, bisexual and other men who have sex with men	\$ 119,246/ 2 years <i>Funded in partnership with the Canadian Institutes of Health Research</i> 
<i>Burke, John</i> University of Victoria	Defining the molecular mechanism of activation of oncogenes in the Akt pathway	\$ 120,000/ 2 years





2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Copeland, John</i> University of Ottawa	A role for FMNL2 in invasion and metastasis	\$ 120,000/ 2 years
<i>Costantino, Santiago</i> Centre de recherche de l'Hôpital Maisonneuve-Rosemont	Exploiting single cell capture to study molecular mechanisms of DNA double strand break repair	\$ 120,000/ 2 years
<i>Di Noia, Javier</i> Institut de recherches cliniques de Montréal (IRCM)	Regulation of proliferation and differentiation by PRMT1 in B cells and B cell lymphoma.	\$ 120,000/ 2 years
<i>Eszlinger, Markus</i> University of Calgary	Diagnostic potential of differentially expressed microRNAs in mutation-negative thyroid nodules with a indeterminate Fine- Needle Aspiration Cytology result	\$ 118,843.20/ 2 years


2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Fahlman, Richard</i> University of Alberta	Investigating how the differences in ribosomes can alter the expression of genes in cancer	\$ 116,268/ 2 years <i>Funded in partnership with the Canadian Institutes of Health Research</i> 
<i>Ferron, Mathieu</i> Institut de recherches cliniques de Montréal (IRCM)	Role of the vitamin K reductase VKORC1L1 in hepatocellular carcinoma	\$ 120,000/ 2 years <i>Funded in partnership with the Environment-Cancer Fund™ of the Cancer Research Society and Read for the Cure.</i> 
<i>Fradet-Turcotte, Amélie</i> CHU de Québec research Center - Université Laval	Characterization of PTM-associated mutations that alter signaling network in breast and ovarian cancers.	\$ 120,000/ 2 years <i>Funded in partnership with the Canadian Institutes of Health Research</i> 
<i>Franco, Eduardo L.</i> McGill University	Validation of epigenetic markers in cervical carcinogenesis	\$ 119,914.99/ 2 years <i>Funded in partnership with the Canadian Institutes of Health Research</i> 




2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Gallinger, Steven</i> University Health Network	GATA6 immunohistochemistry as a prognostic and predictive biomarker in the ESPAC and PRODIGE studies of adjuvant chemotherapy for resected pancreatic cancer	\$ 81,500/ 2 years <i>Funded in partnership with the Rob Lutterman Memorial Fund</i>  Rob Lutterman Memorial Fund
<i>Gerarduzzi, Casimiro</i> Centre de recherche de l'Hôpital Maisonneuve-Rosemont	The role of SMOC2 in renal cell carcinoma	\$ 120,000/ 2 years <i>Funded in partnership with the Kidney Cancer Research Network of Canada and Kidney Cancer Canada</i>  KCRNC KIDNEY CANCER RESEARCH NETWORK OF CANADA RRCRC RÉSEAU DE RECHERCHE SUR LE CANCER DU REIN DU CANADA  Cancer du rein CANADA Kidney Cancer CANADA
<i>Giroux, Véronique</i> Université de Sherbrooke	Tumour-initiating capacity of Krt15+ stem cells in colon cancer	\$ 120,000/ 2 years
<i>Gorski, Sharon</i> BC Cancer	Deciphering a contribution by Parkinson's susceptibility gene LRRK2 to lung cancer immunosuppression	\$ 120,000/ 2 years <i>Funded in partnership with the Canadian Institutes of Health Research</i>  CIHR IRSC Canadian Institutes of Health Research / Instituts de recherche en santé du Canada


2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Gratton, Jean-Philippe Université de Montréal	Implication of cell junctions for PAK2-mediated signaling in endothelial cells and in tumour angiogenesis	\$ 120,000/ 2 years
Grewal, Savraj University of Calgary	The target of rapamycin (TOR) and regulation of a mitochondrial metabolic switch in growth control	\$ 120,000/ 2 years
Guérin, Sylvain Université Laval	Serotonin receptor 2B (HTR2B) : modulation of its expression and contribution to the tumorigenic and metastatic properties of uveal melanoma	\$ 120,000/ 2 years
Guimond, Martin Centre de Recherche de l'Hôpital Maisonnette-Rosemont	Restoring immunity after allogeneic stem cell transplantation and GVHD	\$ 120,000/ 2 years <i>Funded in partnership with the Katherine Campbell Macdonald Memorial Fund</i>  <u>Fonds commémoratif Katherine Campbell MacDonald Memorial Fund</u>





2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Gujar, Shashi</i> Dalhousie University	Targeting brain tumour-initiating cells via p73-mediated regulation of proline regulatory axis	\$ 120,000/ 2 years <i>Funded in partnership with the Beatrice Hunter Cancer Research Institute</i>  BEATRICE HUNTER Cancer Research Institute Evolving Cancer Research in Atlantic Canada
<i>Haibe-Kains, Benjamin</i> University Health Network	Alternatively and trans-spliced isoforms as a new class of biomarkers of response to cytotoxic and targeted therapies in metastatic triple-negative breast cancer	\$ 120,000/ 2 years <i>Funded in partnership with the Canadian Institutes of Health Research</i>  CIHR IRSC Canadian Institutes of Health Research / Instituts de recherche en santé du Canada
<i>Hakem, Razq</i> University Health Network	Investigation of mechanisms leading to synthetic lethality of BRCA-associated cancers	\$ 120,000/ 2 years <i>Funded in partnership with the Canadian Institutes of Health Research</i>  CIHR IRSC Canadian Institutes of Health Research / Instituts de recherche en santé du Canada
<i>Hebb, Matthew</i> Western University	Defining the potential of low intensity intratumoral modulation therapy-based platforms to treat high fatality brain cancers	\$ 120,000/ 2 years




2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Hitt, Mary</i> University of Alberta	Combination of a novel TRAIL-expressing oncolytic virus with a caspase-3 activator for treatment of granulosa cell tumours	\$ 120,000/ 2 years <i>Funded in partnership with the Granulosa Cell Tumour Research Foundation</i>  Granulosa Cell Tumour Research Foundation Working to discover effective treatments for GCT of the ovary
<i>Huot, Marc-Étienne</i> Université Laval	Defining the mechanism of oncometabolite-mediated DEPTOR degradation in brain cancer	\$ 120,000/ 2 years
<i>Jasmin, Bernard</i> University of Ottawa	Defining the novel roles of Staufen1 in rhabdomyosarcoma and its therapeutic potential	\$ 120,000/ 2 years
<i>Jeannotte, Lucie</i> Université Laval	Characterization of the role of the Yin Yang1 (YY1) transcription factor in pleuropulmonary blastoma	\$ 120,000/ 2 years

2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Kekre, Natasha</i> Ottawa Hospital Research Institute	Enhancing the immunogenicity of autologous oncolytic virus infected cell vaccines for the treatment of acute leukemia	\$ 120,000/ 2 years
<i>Kim, John</i> University Health Network	Developing advanced radiomics based prognostic models for tumour recurrence following chemo radiation therapy in anal cancer	\$ 120,000/ 2 years  <i>Funded in partnership with the The Environment-Cancer Fund™ of the Cancer Research Society and Read for the Cure.</i> 
<i>Koromilas, Antonis</i> Lady Davis Institute for Medical Research	eIF2 phosphatase inhibitors in the treatment of Trastuzumab-resistant breast cancer	\$ 120,000/ 2 years <i>Funded in partnership with the Canadian Institutes of Health Research</i> 
<i>Koushik, Anita</i> Centre hospitalier de l'Université de Montréal	Lifetime vitamin D exposure and the risk of ovarian cancer	\$ 120,000/ 2 years <i>Funded in partnership with the Canadian Institutes of Health Research</i> 

2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Labbé, Jean-Claude Université de Montréal	Regulation of RhoA activity by the flavin monooxygenase OSGN-1/OSGIN	\$ 120,000/ 2 years
Laprise, Patrick Research Center of the CHU de Québec-Université Laval	Identification and validation of compounds targeting tumour growth and cancer-induced cachexia	\$ 119,991/ 2 years <i>Funded in partnership with the Charlotte Légaré Memorial Fund</i>  Charlotte Légaré Memorial Fund
Lewis, Stephen Atlantic Cancer Research Institute	Characterization of the mechanism by which the translation initiation factor eIF3e regulates epithelial-to-mesenchymal transition	\$ 120,000/ 2 years <i>Funded in partnership with the Beatrice Hunter Cancer Research Institute</i>  BEATRICE HUNTER Cancer Research Institute <small>Evolving Cancer Research in Atlantic Canada</small>
Lok, Benjamin University Health Network	Defining the mechanism of a Skp1-Cul1-F-box (SCF) E3 ubiquitin ligase complex to understand therapeutic resistance in small cell lung cancer	\$ 120,000/ 2 years <i>Funded in partnership with the Katherine Campbell Macdonald Memorial Fund</i>  Fonds commémoratif Katherine Campbell MacDonal d Memorial Fund


2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Lorimer, Ian Ottawa Hospital Research Institute	PREX1 signalling in glioblastoma	\$ 120,000/ 2 years
Lu, Yu McMaster University	The role of the splicing factor RBM17 in leukemic stem cell functions	\$ 120,000/ 2 years
Luyt, Leonard University of Western Ontario	Development and evaluation of PET agents targeting Enhancer of Zeste Homologue 2 (EZH2) for pancreatic cancer imaging	\$ 120,000/ 2 years <i>Funded in partnership with the Charlotte Légaré Memorial Fund</i>
Mahoney, Douglas University of Calgary	The microbiome in Smac mimetic-based immunotherapy of cancer	\$ 120,000/ 2 years






Charlotte Légaré
Memorial Fund



2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Marignani, Paola Dalhousie University	Characterization of loss of tumour suppressors LKB1 and SMARCA4 in lung cancer	\$ 120,000/ 2 years
McCaffrey, Luke McGill University	Targeting novel cancer-promoting pathways in breast cancer	\$ 120,000/ 2 years <i>Funded in partnership with the Canadian Institutes of Health Research</i> 
Melichar, Heather Centre de recherche de l'Hôpital Maisonneuve-Rosemont	The anti-tumour potential of targeting an "orphan" tumour necrosis factor receptor	\$ 120,000/ 2 years
Miller, Jr, Wilson H. Lady Davis Institute for Medical Research	Identifying novel cellular functions and biological outcomes for MNK1	\$ 117,500/ 2 years


2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Monument, Michael University of Calgary	STING activation as a therapeutic modality for sarcoma	\$ 118,680/ 2 years <i>Funded in partnership with the C¹⁷ Council</i> 
O'Brien, Catherine University Health Network	Inhibition of the CBP/p300 bromodomain activity increases chemosensitivity of colorectal cancer to 5-Fluorouracil by restoring p53 function	\$ 120,000/ 2 years <i>Funded in partnership with the Katherine Campbell Macdonald Memorial Fund</i>  Fonds commémoratif Katherine Campbell MacDonal Memorial Fund
Plante, Isabelle Institut national de la recherche scientifique (INRS)	Exposure to brominated flame retardants during sensitive periods of development: an increased risk for breast and ovarian cancers?	\$ 120,000/ 2 years <i>Funded in partnership with the Quebec Breast Cancer Foundation</i>  Quebec Breast Cancer Foundation
Rafei, Moutih Université de Montréal	Antigen cross-presenting mesenchymal stem cells for cancer immunotherapy	\$ 120,000/ 2 years


2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Ramanathan, Sheela</i> Université de Sherbrooke	Mechanism of IL-15-mediated protection against neoplastic transformation of thymocytes	\$ 120,000/ 2 years
<i>Rivera, Barbara</i> Lady Davis Institute for Medical Research	The RAD51 interactome in ovarian and breast cancers	\$ 120,000/ 2 years
<i>Rottapel, Robert</i> University Health Network	Therapeutic opportunities targeting the relaxin autocrine loop in high grade serous ovarian cancer	\$ 120,000/ 2 years <i>Funded in partnership with the Ovarian Cancer Canada</i>  Ovarian Cancer Canada Cancer de l'ovaire Canada
<i>Rullo, Anthony</i> McMaster University	New covalent antibody anchoring technology to develop novel target tunable, multispecific chemical tumour immunotherapeutics	\$ 120,000/ 2 years <i>Funded in partnership with the Canadian Institutes of Health Research</i>  CIHR IRSC Canadian Institutes of Health Research / Instituts de recherche en santé du Canada



2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Salmena, Leonardo</i> University of Toronto	Investigating the role of phosphoinositide signalling by INPP4B in pancreatic cancer	\$ 120,000/ 2 years <i>Funded in partnership with the Charlotte Légaré Memorial Fund</i>  Charlotte Légaré Memorial Fund
<i>Sangwan, Veena</i> McGill University Health Center	Preclinical testing of personalized therapy in esophago-gastric adenocarcinoma	\$ 120,000/ 2 years
<i>Spagnuolo, Paul</i> University of Guelph	Long chain acyl-CoA dehydrogenase as a novel therapeutic target in acute myeloid leukemia	\$ 120,000/ 2 years
<i>Ursini-Siegel, Josie</i> Lady Davis Institute for Medical Research	Establishing the impact of deregulated oncogenic kinase signaling on the translational machinery during breast cancer metastasis	\$ 120,000/ 2 years

2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Wang, Lisheng University of Ottawa	Co-inhibition of lipid metabolic enzymes and associated pathways for the effective treatment of triple negative breast cancer	\$ 120,000/ 2 years <i>Funded in partnership with the University of Ottawa</i>  uOttawa
Wiper-Bergeron, Nadine University of Ottawa	Prevention of cancer cachexia and reduction of tumour growth via inhibition of C/EBPbeta	\$ 120,000/ 2 years
Wu, Yuliang University of Saskatchewan	Role of hSSB1 in transcriptional regulation and genome integrity maintenance	\$ 120,000/ 2 years
Wurtele, Hugo Université de Montréal	Oncometabolite-induced chromatin modifications and DNA replication stress in brain cancer	\$ 120,000/ 2 years

2019 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Ybarra, Norma</i> McGill University	Radio-selective effects of a natural occurring muscle-derived dipeptide in an orthotopic lung cancer rat model	\$ 120,000/ 2 years <i>Funded in partnership with the Canadian Institutes of Health Research</i>  CIHR IRSC Canadian Institutes of Health Research / Instituts de recherche en santé du Canada
<i>Zogopoulos, George</i> McGill University Health Centre	Elucidating the genetics of pancreatic cancer: functional characterization of SMG1 variants associated with pancreatic cancer susceptibility	\$ 120,000/ 2 years <i>Funded in partnership with the Rob Lutterman Memorial Fund</i>  Rob Lutterman Memorial Fund